219 related articles for article (PubMed ID: 35242673)
41. TCGA database analysis of the tumor mutation burden and its clinical significance in colon cancer.
Chen J; Apizi A; Wang L; Wu G; Zhu Z; Yao H; Chen G; Shi X; Shi B; Tai Q; Shen C; Zhou G; Wu L; He S
J Gastrointest Oncol; 2021 Oct; 12(5):2244-2259. PubMed ID: 34790389
[TBL] [Abstract][Full Text] [Related]
42. Identification of gene expression profiles and immune cell infiltration signatures between low and high tumor mutation burden groups in bladder cancer.
Wu Z; Wang M; Liu Q; Liu Y; Zhu K; Chen L; Guo H; Li Y; Shi B
Int J Med Sci; 2020; 17(1):89-96. PubMed ID: 31929742
[TBL] [Abstract][Full Text] [Related]
43. Pan-cancer analysis of tumor mutation burden sensitive tumors reveals tumor-specific subtypes and hub genes related to immune infiltration.
Wu H; Wang H; Chen Y
J Cancer Res Clin Oncol; 2023 Jul; 149(7):2793-2804. PubMed ID: 35780251
[TBL] [Abstract][Full Text] [Related]
44. ADRB1 was identified as a potential biomarker for breast cancer by the co-analysis of tumor mutational burden and immune infiltration.
Wang J; Zhang X; Li J; Ma X; Feng F; Liu L; Wu J; Sun C
Aging (Albany NY); 2020 Nov; 13(1):351-363. PubMed ID: 33234738
[TBL] [Abstract][Full Text] [Related]
45. Exploration of the immune-related signature and immune infiltration analysis for breast ductal and lobular carcinoma.
Zhang B; Wang Q; Fu C; Jiang C; Ma S
Ann Transl Med; 2019 Dec; 7(23):730. PubMed ID: 32042746
[TBL] [Abstract][Full Text] [Related]
46. Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia.
Wang D; Wang N; Li X; Chen X; Shen B; Zhu D; Zhu L; Xu Y; Yu Y; Shu Y
Gastric Cancer; 2021 Jul; 24(4):823-834. PubMed ID: 33687617
[TBL] [Abstract][Full Text] [Related]
47. Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer.
Xu J; Bao H; Wu X; Wang X; Shao YW; Sun T
Oncol Lett; 2019 Jul; 18(1):449-455. PubMed ID: 31289516
[TBL] [Abstract][Full Text] [Related]
48. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.
Lv J; Zhu Y; Ji A; Zhang Q; Liao G
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32239176
[TBL] [Abstract][Full Text] [Related]
49. Analysis of tumor mutation burden combined with immune infiltrates in endometrial cancer.
Zhang J; An L; Zhou X; Shi R; Wang H
Ann Transl Med; 2021 Apr; 9(7):551. PubMed ID: 33987249
[TBL] [Abstract][Full Text] [Related]
50. Significance of Tumor Mutation Burden Combined With Immune Infiltrates in the Progression and Prognosis of Advanced Gastric Cancer.
Guo X; Liang X; Wang Y; Cheng A; Zhang H; Qin C; Wang Z
Front Genet; 2021; 12():642608. PubMed ID: 34306002
[TBL] [Abstract][Full Text] [Related]
51. Integrating tumor mutational burden and transcriptome expression into prediction of immune checkpoint inhibitor response and prognosis of patients with colon cancer.
Liang L; Jiang W; Zheng Y; Liu TS; Shen XZ; Chen YJ
J Physiol Pharmacol; 2022 Apr; 73(2):. PubMed ID: 35988929
[TBL] [Abstract][Full Text] [Related]
52. Multi-omics analysis reveals prognostic value of tumor mutation burden in hepatocellular carcinoma.
Xu Q; Xu H; Deng R; Wang Z; Li N; Qi Z; Zhao J; Huang W
Cancer Cell Int; 2021 Jul; 21(1):342. PubMed ID: 34217320
[TBL] [Abstract][Full Text] [Related]
53. Ferroptosis biomarkers predict tumor mutation burden's impact on prognosis in HER2-positive breast cancer.
Shi JY; Che X; Wen R; Hou SJ; Xi YJ; Feng YQ; Wang LX; Liu SJ; Lv WH; Zhang YF
World J Clin Oncol; 2024 Mar; 15(3):391-410. PubMed ID: 38576597
[TBL] [Abstract][Full Text] [Related]
54. Comparative Analysis of Mutation Status and Immune Landscape for Squamous Cell Carcinomas at Different Anatomical sites.
Ti W; Wei T; Wang J; Cheng Y
Front Immunol; 2022; 13():947712. PubMed ID: 35935970
[TBL] [Abstract][Full Text] [Related]
55. PRLHR Immune Genes Associated With Tumor Mutation Burden can be Used as Prognostic Markers in Patients With Gliomas.
Liu Y; Xiang J; Peng G; Shen C
Front Oncol; 2022; 12():620190. PubMed ID: 35800054
[TBL] [Abstract][Full Text] [Related]
56. Identification of Three Core Secretome Genes Associated with Immune Infiltration in High Tumor Mutation Burden Across 14 Major Solid Tumors.
Wu H; Wang H; Jiang Z; Chen Y
Int J Gen Med; 2021; 14():6755-6767. PubMed ID: 34703282
[TBL] [Abstract][Full Text] [Related]
57. Construction of a prognostic risk assessment model for HER2 + breast cancer based on autophagy-related genes.
Wang F; Fang L; Fu B; Fan C
Breast Cancer; 2023 May; 30(3):478-488. PubMed ID: 36856932
[TBL] [Abstract][Full Text] [Related]
58. Comprehensive Analysis of the Relationships Between Tumor Mutation Burden With Immune Infiltrates in Cervical Cell Carcinoma.
Zhou C; Li C; Peng S; Zhou L; Li H
Front Mol Biosci; 2020; 7():582911. PubMed ID: 33134320
[TBL] [Abstract][Full Text] [Related]
59. Tumour mutation burden and infiltrating immune cell subtypes influenced the breast cancer prognosis.
Li J; Liu H; Han M; Jiang H; He J; Miao J; Liu Y
Transl Cancer Res; 2024 May; 13(5):2208-2221. PubMed ID: 38881919
[TBL] [Abstract][Full Text] [Related]
60. The prognostic value of tumor mutation burden in
Jiao XD; He X; Qin BD; Liu K; Wu Y; Liu J; Hou T; Zang YS
J Thorac Dis; 2019 Nov; 11(11):4507-4515. PubMed ID: 31903239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
